( NYSE:AGN )

News from Allergan plc A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Dec 12, 2017, 08:51 ET Allergan Receives FDA Clearance For the CoolSculpting® Treatment To Improve Appearance Of Lax Tissue In The Double Chin

Allergan plc (NYSE: AGN) today announced that the CoolSculpting® treatment is the first and only non-surgical fat reduction technology to be...


Nov 29, 2017, 08:01 ET Allergan's Migraine Leadership Recognized with Enrico Greppi Award for Excellence in Headache Research

Allergan plc, (NYSE: AGN), a leading global pharmaceutical company, is pleased to announce that its manuscript, "Fluctuations in Episodic and...


Nov 22, 2017, 16:15 ET Allergan to Present at the 2017 Citi Global Healthcare Conference

Allergan plc (NYSE: AGN), a leading global biopharmaceutical company, today announced that Chief Commercial Officer William Meury will present at...


Nov 16, 2017, 08:00 ET Allergan to Present at the Evercore ISI 2017 Biopharma Catalyst/Deep Dive Conference

Allergan plc (NYSE: AGN), a leading global biopharmaceutical company, today announced that David Nicholson, Allergan's Chief Research and...


Nov 14, 2017, 08:00 ET Overactive Bladder Causes Significant Burden, Regardless of Age Amongst Adults

Allergan, Inc. (NYSE: AGN), in partnership with the National Association For Continence (NAFC), today announced the results of a new survey that...


Nov 13, 2017, 07:35 ET Allergan Receives FDA Approval For Use of VRAYLAR™ (cariprazine) in the Maintenance Treatment of Schizophrenia

Allergan plc (NYSE: AGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA)...


Nov 08, 2017, 08:00 ET Allergan to Present Dynamic Eye Care Data at American Academy of Ophthalmology Meeting in New Orleans

Allergan plc (NYSE: AGN), a leading global pharmaceutical company, today announced its data will be presented at the annual American Academy...


Nov 07, 2017, 07:00 ET Allergan to Present at Credit Suisse 26th Annual Healthcare Conference

Allergan plc (NYSE: AGN), a leading global biopharmaceutical company, today announced that William Meury, Allergan's Chief Commercial Officer, will...


Nov 01, 2017, 07:00 ET Allergan Reports Solid Top-Line Execution in Third Quarter 2017 with 11% Increase in GAAP Net Revenues to $4.03 Billion

Allergan plc (NYSE: AGN) today reported its third quarter 2017 continuing operations performance. Third Quarter 2017 Continuing Operations...


Oct 31, 2017, 16:01 ET Allergan Presented New Phase 3 Data of Ulipristal Acetate in Women with Uterine Fibroids at the American Society for Reproductive Medicine Annual Congress

Allergan plc (NYSE: AGN) presented new analyses of VENUS II, the second of two pivotal Phase 3 clinical trials evaluating the efficacy and safety...


Oct 30, 2017, 08:00 ET Allergan Receives Approval for Ozurdex® (Dexamethasone Intravitreal Implant 0.7 mg) in China for the Treatment of Retinal Vein Occlusion (RVO)

Allergan plc (NYSE: AGN) announced today that it has received an Imported Drugs License (IDL) from the Chinese Food and Drug Administration (CFDA)...


Oct 27, 2017, 08:00 ET Allergan Board of Directors Announces Fourth Quarter 2017 Cash Dividend and Increases Quarterly Cash Dividend for 2018

Allergan plc (NYSE: AGN) today announced the record and payment dates for a cash dividend of $0.70 per ordinary share for the fourth quarter of...


Oct 23, 2017, 08:00 ET Allergan to Present Latest Studies of Ulipristal Acetate for Uterine Fibroids at the American Society for Reproductive Medicine 73rd Annual Congress

Allergan plc (NYSE: AGN) today announced that it has three oral presentations and a poster being presented at the American Society for Reproductive...


Oct 18, 2017, 18:45 ET Allergan Issues Investor FAQ on Federal District Court RESTASIS® Patent Decision

Allergan plc (NYSE:AGN), a leading global biopharmaceutical company, today issued an FAQ document responding to investor questions following the...


Oct 16, 2017, 13:45 ET U.S. District Court for the Eastern District of Texas Issues Adverse Trial Decision Concerning RESTASIS® (Cyclosporine Ophthalmic Emulsion) 0.05% Patents

Allergan plc (NYSE: AGN), a leading global biopharmaceutical company, today acknowledged that the U.S. District Court for the Eastern District of...


Oct 16, 2017, 08:01 ET Allergan to Present New Data at the World Congress of Gastroenterology at ACG 2017

Allergan plc (NYSE: AGN) today announced that new data from its gastroenterology portfolio will be featured at the World Congress of...


Oct 12, 2017, 16:15 ET Allergan Announces Settlement on RESTASIS® (Cyclosporine Ophthalmic Emulsion) 0.05% Patent Litigation with InnoPharma, Inc.

Allergan plc (NYSE: AGN), a leading global pharmaceutical company, and its subsidiaries today announced that the Company has reached an agreement...


Oct 11, 2017, 08:01 ET Allergan to Present Data From More Than 20 Abstracts at the 2017 Fall Clinical Dermatology Conference

Allergan (NYSE: AGN), a leading global pharmaceutical company, announced today that it will present 22 abstracts at the 2017 Fall Clinical...


Oct 10, 2017, 08:01 ET Allergan Announces that the FDA Accepts New Drug Application for Ulipristal Acetate for Uterine Fibroids

Allergan plc (NYSE: AGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for...


Oct 09, 2017, 08:30 ET Allergan to Present New Dry Eye Data at the American Academy of Optometry Meeting in Chicago

Allergan plc (NYSE: AGN), a leading global pharmaceutical company, today announced several Allergan-supported abstracts were selected for poster...


Oct 05, 2017, 12:05 ET Allergan Presents Data From Seventeen Abstracts At The 2017 American Society For Dermatologic Surgery Meeting In Chicago

Allergan (NYSE: AGN), a leading global pharmaceutical company, announced today that it will present 17 Allergan-supported abstracts at the 2017...


Oct 04, 2017, 08:01 ET Allergan To Present New Data From Its Anti-Infectives Portfolio At IDWeek 2017 In San Diego

Allergan plc (NYSE: AGN) a leading global pharmaceutical company committed to improving outcomes and meeting critical needs in infectious diseases,...


Oct 03, 2017, 07:31 ET FDA Approves BOTOX® Cosmetic (OnabotulinumtoxinA) for the Temporary Improvement in the Appearance of Moderate to Severe Forehead Lines Associated with Frontalis Muscle Activity In Adults

Today Allergan plc (NYSE:AGN) announced the FDA approval of BOTOX® Cosmetic for its third indication, the temporary improvement in the appearance...


Oct 02, 2017, 08:00 ET FDA Accepts Supplemental New Drug Application (sNDA) filing for AVYCAZ® (ceftazidime and avibactam)

Allergan plc (NYSE: AGN), a leading global pharmaceutical company, today announced the U.S. Food and Drug Administration (FDA) has accepted a...


Oct 02, 2017, 07:30 ET Allergan to Report Third Quarter 2017 Earnings and Host Conference Call and Webcast

Allergan plc (NYSE: AGN) today announced it intends to release third quarter 2017 financial results on Wednesday, November 1, 2017, prior to the...